Shares of Arvinas Inc (NASDAQ:ARVN) have been assigned an average recommendation of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $50.00.
A number of brokerages recently commented on ARVN. Wedbush lifted their target price on shares of Arvinas from $39.00 to $60.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Cantor Fitzgerald lifted their target price on shares of Arvinas from $42.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Zacks Investment Research lowered shares of Arvinas from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright started coverage on shares of Arvinas in a report on Thursday, December 19th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, BidaskClub lowered shares of Arvinas from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 1st.
Shares of NASDAQ:ARVN opened at $50.30 on Monday. The stock has a market cap of $1.78 billion, a PE ratio of -24.30 and a beta of 2.69. The company’s fifty day moving average is $48.04 and its 200 day moving average is $32.30. Arvinas has a 52 week low of $14.06 and a 52 week high of $54.95. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.03.
A number of institutional investors have recently made changes to their positions in ARVN. Canaan Partners IX LLC bought a new stake in Arvinas in the 4th quarter worth $184,476,000. RA Capital Management L.P. boosted its stake in shares of Arvinas by 120.8% during the 4th quarter. RA Capital Management L.P. now owns 3,672,872 shares of the company’s stock valued at $150,918,000 after purchasing an additional 2,009,360 shares in the last quarter. 5AM Venture Management LLC bought a new stake in shares of Arvinas during the 4th quarter valued at about $56,639,000. Perceptive Advisors LLC bought a new stake in shares of Arvinas during the 4th quarter valued at about $16,436,000. Finally, ArrowMark Colorado Holdings LLC boosted its stake in shares of Arvinas by 657.1% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 378,560 shares of the company’s stock valued at $15,555,000 after purchasing an additional 328,560 shares in the last quarter. 61.36% of the stock is currently owned by institutional investors and hedge funds.
Arvinas Company Profile
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.